Abstract
ZR-75-1, a human breast cancer cell line, has been grown in hormone- supplemented medium without serum. The factors required for optimal growth include 17β-estradiol, insulin, transferrin, dexamethasone, and L- triiodothyronine. If estradiol, insulin, or L-triiodothyronine is omitted, cells cease division within 7 days, but viability is retained for at least 14 days. Omission of transferrin leads to cell death within 7 days. The cells have been continuously maintained in this environment without morphological alteration or cessation of growth for more than 5 months. Addition of the anti-estrogen, Tamoxifen (10-6 M), inhibited cells below the growth rate seen when estradiol was omitted from the medium, even when Tamoxifen was added 4 days and two medium changes after the removal of estradiol from the medium, thus suggesting an action of Tamoxifen which may be independent of competition with estradiol. The availability of a human breast cancer cell line that can be propagated in hormone-supplemented medium without serum should aid in the study of the mechanisms by which hormones effect cell growth.
| Original language | English |
|---|---|
| Pages (from-to) | 3823-3829 |
| Number of pages | 7 |
| Journal | Cancer Research |
| Volume | 38 |
| Issue number | 11 I |
| State | Published - Dec 1 1978 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Growth of a human breast cancer cell line in serum-free hormone-supplemented medium. / Allegra, J. C.; Lippman, Marc E.
In: Cancer Research, Vol. 38, No. 11 I, 01.12.1978, p. 3823-3829.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Growth of a human breast cancer cell line in serum-free hormone-supplemented medium
AU - Allegra, J. C.
AU - Lippman, Marc E
PY - 1978/12/1
Y1 - 1978/12/1
N2 - ZR-75-1, a human breast cancer cell line, has been grown in hormone- supplemented medium without serum. The factors required for optimal growth include 17β-estradiol, insulin, transferrin, dexamethasone, and L- triiodothyronine. If estradiol, insulin, or L-triiodothyronine is omitted, cells cease division within 7 days, but viability is retained for at least 14 days. Omission of transferrin leads to cell death within 7 days. The cells have been continuously maintained in this environment without morphological alteration or cessation of growth for more than 5 months. Addition of the anti-estrogen, Tamoxifen (10-6 M), inhibited cells below the growth rate seen when estradiol was omitted from the medium, even when Tamoxifen was added 4 days and two medium changes after the removal of estradiol from the medium, thus suggesting an action of Tamoxifen which may be independent of competition with estradiol. The availability of a human breast cancer cell line that can be propagated in hormone-supplemented medium without serum should aid in the study of the mechanisms by which hormones effect cell growth.
AB - ZR-75-1, a human breast cancer cell line, has been grown in hormone- supplemented medium without serum. The factors required for optimal growth include 17β-estradiol, insulin, transferrin, dexamethasone, and L- triiodothyronine. If estradiol, insulin, or L-triiodothyronine is omitted, cells cease division within 7 days, but viability is retained for at least 14 days. Omission of transferrin leads to cell death within 7 days. The cells have been continuously maintained in this environment without morphological alteration or cessation of growth for more than 5 months. Addition of the anti-estrogen, Tamoxifen (10-6 M), inhibited cells below the growth rate seen when estradiol was omitted from the medium, even when Tamoxifen was added 4 days and two medium changes after the removal of estradiol from the medium, thus suggesting an action of Tamoxifen which may be independent of competition with estradiol. The availability of a human breast cancer cell line that can be propagated in hormone-supplemented medium without serum should aid in the study of the mechanisms by which hormones effect cell growth.
UR - http://www.scopus.com/inward/record.url?scp=0018168638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018168638&partnerID=8YFLogxK
M3 - Article
C2 - 212180
AN - SCOPUS:0018168638
VL - 38
SP - 3823
EP - 3829
JO - Journal of Cancer Research
JF - Journal of Cancer Research
SN - 0099-7013
IS - 11 I
ER -